Subcutaneous Antipsoriatic Drug Development Services

The development of subcutaneous antipsoriatic therapies has gained traction due to their potential to enhance drug delivery. At Ace Therapeutics, we specialize in providing preclinical contract services to support the development of subcutaneous administration of antipsoriatic drugs.

Introduction to Subcutaneous Administration of Antipsoriatic Drugs

Psoriasis arises from a complex interaction of genetic, environmental, and immunological factors. While conventional treatments, such as topical agents and phototherapy, may benefit mild cases, individuals with moderate to severe psoriasis often require advanced therapeutic options. Biologics such as ustekinumab and secukinumab, which have shown significant efficacy in managing moderate to severe psoriasis, can be administered subcutaneously. This route bypasses the gastrointestinal tract, reducing systemic side effects and enhancing the bioavailability of the active compounds.

The absorption rates and pharmacokinetics can vary significantly based on the injection site, highlighting the importance of rigorous preclinical studies to optimize drug formulation and administration techniques. Subcutaneous (SC) administration of antipsoriatic drugs has gained significant traction due to its potential for improved overall compliance, targeted delivery, and sustained therapeutic effects. Moreover, SC injections can enhance drug absorption and provide a sustained release profile, which is crucial for maintaining therapeutic levels in chronic disease like psoriasis.

Fig. 1 Subcutaneous injection of hUC-MSCs ameliorates psoriasislike skin infammation. (Chen Y, et al., 2022)

Comprehensive Subcutaneous Antipsoriatic Drug Development Services

Ace Therapeutics provides a comprehensive suite of services for subcutaneous antipsoriatic drug development, employing a comprehensive approach that encompasses all phases of preclinical research.

Pharmacokinetic and Pharmacodynamic Services

We conduct detailed pharmacokinetic (PK) studies to evaluate the absorption, distribution, metabolism, and excretion of antipsoriatic agents, alongside pharmacodynamic (PD) assessments to understand their therapeutic effects on disease endpoints.

• Bioanalytical Assays: Utilizing enzyme-linked immunosorbent assay (ELISA) and liquid chromatography-mass spectrometry (LC-MS) to quantify drug concentrations in biological samples, allowing for precise PK profiling.
• Comparative Studies: Assessing the impact of different subcutaneous injection sites on drug absorption and therapeutic efficacy, generating critical data to inform dosing strategies.

Formulation Development

Our formulation development services focus on developing stable and effective drug formulations for subcutaneous delivery.

• Lyophilization: Enhancing the stability and shelf-life of biologics and evaluate efficacy upon reconstitution.
• Nanoformulation Technologies: Developing nanoemulsions and liposomal formulations that improve drug solubility and bioavailability, facilitating better absorption through subcutaneous tissue.

Preclinical Models and Toxicology Services

• Disease Models: Utilizing swine and murine models that closely mimic human psoriasis to evaluate drug efficacy and safety.
• Toxicology Assessments: Conducting acute and chronic toxicity studies to determine the safety profile of drug candidates, along with immunogenicity evaluations to assess potential adverse immune responses.

Our Advantages in Subcutaneous Antipsoriatic Drug Development

• Expertise in Antipsoriatic Drug Development: Our extensive experience with monoclonal antibodies and various biologics, as well as other therapeutic modalities, enables us to navigate the complexities of drug development effectively.
• Animal Model Development: Utilizing various animal models, including swine, we conduct detailed pharmacokinetic studies that reflect human physiology closely. These models allow us to explore the impact of different administration sites on drug absorption and pharmacokinetics.
• Tailored Solutions: Our services are customizable, allowing us to tailor our approach to meeting specific needs. Whether it's optimizing formulations or conducting in-depth pharmacokinetic studies, Ace Therapeutics is committed to providing flexible solutions.

The advancement of subcutaneous antipsoriatic drug development represents a significant opportunity to improve therapeutic outcomes. At Ace Therapeutics, we are dedicated to providing high-quality preclinical CRO services that support our clients in navigating the complexities of drug development. Contact us today to learn more about how we can support your drug development projects.